Molecular targets related to inflammation and insulin resistance and potential interventions

Sandro M Hirabara1, Renata Gorjão, Marco A Vinolo

  • 1Institute of Physical Activity Sciences and Sports, Cruzeiro do Sul University, 01506-000 São Paulo, SP, Brazil. sandromh@yahoo.com.br

Insights

Inflammation and insulin resistance are linked in chronic diseases like obesity and diabetes. Understanding their molecular basis and targeting inflammatory pathways may lead to new therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pathophysiology

Background:

  • Inflammation and insulin resistance are prevalent in chronic conditions including obesity, type 2 diabetes mellitus, metabolic syndrome, cancer, and cardiovascular diseases.
  • A significant relationship exists between inflammation and insulin resistance, though the underlying molecular mechanisms require further elucidation.

Purpose of the Study:

  • To discuss the molecular underpinnings of insulin resistance and inflammation.
  • To explore how inflammatory pathways molecularly interfere with insulin action.
  • To review molecularly targeted interventions and biotechnological advancements for treating associated disorders.

Main Methods:

  • Literature review focusing on molecular mechanisms.
  • Analysis of inflammatory pathways impacting insulin signaling.
  • Exploration of current and emerging therapeutic strategies.

Main Results:

  • Detailed discussion on the molecular basis of insulin resistance and inflammation.
  • Identification of inflammatory pathways that disrupt insulin signaling.
  • Overview of potential therapeutic targets and biotechnological approaches.

Conclusions:

  • Elucidating the molecular interplay between inflammation and insulin resistance is crucial for developing effective treatments.
  • Targeting specific molecular pathways offers promise for managing chronic diseases characterized by these conditions.
  • Biotechnological research is advancing the development of novel therapies for inflammation and insulin resistance.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...